The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
The Singularity – The Promise of Technology?
The singularity—or more accurately, the technological singularity—“is a hypothetical future point in time at which technological growth becomes…
A Whistleblower Speaking Truth to Power
Whistleblowers protect the public interest by exposing harmful misconduct and maintaining trust in institutions. However, they must choose…
Risk-Based Testing – A Comprehensive Guide
Content 1. What is the Purpose of Risk-Based Testing? 2. How Risk-Based Testing Differs from other Testing Approaches?…
